
ABSTRACT

The present invention relates to a secondary cataract inhibitor comprising as the active ingredient N-(3,4-dimethoxycinnamoyl)anthranilic acid represented by the formula:



or a pharmaceutically acceptable salt thereof, which has an inhibitory activity on posterior capsule opacification formation after cataract surgery and is useful for the prevention or treatment of secondary cataract.